Full name
"ANIMAL PHARMA OLSZTYN-KRUSZYŃSKI, PIECZKOWSKI, RAPKOWSKI" SPÓŁKA JAWNA
uses securityreCAPTCHA
"ANIMAL PHARMA OLSZTYN-KRUSZYŃSKI, PIECZKOWSKI, RAPKOWSKI" SPÓŁKA JAWNA
UL. DĄBROWSZCZAKÓW 39, 10-542 OLSZTYN
TAX ID7393658704
Rate company:
"ANIMAL PHARMA OLSZTYN-KRUSZYŃSKI, PIECZKOWSKI, RAPKOWSKI" SPÓŁKA JAWNA
TAX ID7393658704
KRS0000293682
address
UL. DĄBROWSZCZAKÓW 39, 10-542 OLSZTYN
Categories
Main category
Is this your company?Update company information to get new customers, get notified of new reviews, and more!
Register Data
NIP
7393658704
REGON
280255556
KRS
0000293682
Legal form
general partnership
Register Address
UL. DĄBROWSZCZAKÓW 39, 10-542 OLSZTYN
Date of registration in KRS
2007-11-27
Date of commencement of economic activity
2007-11-27
Act signature
OL.VIII NS-REJ.KRS/3101/25/732/ADE
Pkd codes
75.00.Z - Veterinary activities
70.22.Z - Head office activities and management consultancy
72.19.Z - Scientific research and development activities
73.12.D - Advertising through mass media
73.20.Z - Market research and public opinion polling
96.09.Z - Individual service activities
Payer VAT status
Active
Vat list bank account(s)
PL05 2490 0005 0000 4530 2798 0224 
PL11 2490 0005 0000 4612 4557 0535 PL21 2490 0005 0000 4600 6442 0658 Financial data
Net sales [PLN]
Gross profit / loss [PLN]
Automatically generated based on financial statements from KRS Registry
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale  | 3,5 | 4,9 | 4,9 | -0,8 |
Gross profit (loss) | 3,7 | 5 | 5 | -1,2 |
EBITDA | 3,8 | 5,1 | 5,1 | -1,1 |
Short time liabilities | 3,2 | 3,1 | 3,9 | 25,3 |
Other operating costs | 0,3 | 0,1 | 0 | -16,6 |
Equity capital | 3,7 | 5 | 5 | -1,2 |
Operating profit (EBIT) | 3,7 | 5 | 4,9 | -0,9 |
Assets | 6,9 | 8,1 | 8,9 | 8,9 |
Net profit (loss) | 3,7 | 5 | 5 | -1,2 |
Cash | 1,7 | 1,1 | 1,3 | 13,7 |
Net income from sale | 16,8 | 21 | 23,5 | 12,2 |
Liabilities and provisions for liabilities | 3,2 | 3,1 | 3,9 | 25,3 |
Working assets | 5,2 | 6,7 | 7,5 | 12,2 |
Other income costs | 0,5 | 0,1 | 0,1 | -16,7 |
Depreciation | 0,1 | 0,1 | 0,1 | -8 |
% | % | % | p.p. | |
Profitability of capital | 99,6 | 99,7 | 99,7 | 0 |
Equity capital to total assets | 53,3 | 61,8 | 56 | -5,8 |
Gross profit margin | 21,9 | 23,9 | 21 | -2,9 |
EBITDA Margin | 22,3 | 24,4 | 21,5 | -2,9 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 70 | 54 | 60 | 6 |
Current financial liquidity indicator | 1.5940425395965576 | 2.142993211746216 | 1.9200315475463867 | -0,2 |
Net dept to EBITDA | -0.45048239827156067 | -0.2170841246843338 | -0.24951264262199402 | 0 |
Financial statements
01-01-2023 - 31-12-2023
Annual financial report
Download xml01-01-2023 - 31-12-2023
Annual financial report
Download docx01-01-2023 - 31-12-2023
Resolution or decision approving the annual financial statements
Download pdf01-01-2023 - 31-12-2023
Resolution on profit distribution or loss coverage
Download pdfShow more (1)
uses security reCAPTCHA
Opinions
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane
0/ 5.0
How do you rate this company?
Your opinion matters to us.